Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.9 USD | -0.93% | +21.08% | +164.26% |
07/05 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
06/05 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+164.26% | 72Cr | |
-0.09% | 4.21TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.92TCr | |
+11.18% | 2.6TCr | |
-21.95% | 1.89TCr | |
+8.61% | 1.32TCr | |
+24.73% | 1.22TCr | |
+28.31% | 1.22TCr | |
-6.26% | 1.14TCr |
- Stock Market
- Equities
- STOK Stock
- News Stoke Therapeutics, Inc.
- Stoke Therapeutics : Reports Positive Data From Study of STK-001 in Patients With Dravet Syndrome; Shares Rise 4%